# US 2025/0367157 A1 · Composition for use in the treatment of diseases associated with dysfunction of mitochondriae

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367157 A1
- Document ID: US20250367157A1
- Status: Published application
- Kind: A1
- Application number: 18/877,698
- Filed: 2023-06-30
- Published: 2025-12-04
- Earliest claimed: 2022-07-01
- Applicants: Iuf Leibniz-Institut FüR Umweltmedizinische Forschung GmbH
- Inventors: Jean KRUTMANN; Marc MAJORA
- Web page: https://patentgrep.com/patent/US20250367157A1

## CPC

- A61K 31/205: Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A61K 31/14: Quaternary ammonium compounds, e.g. edrophonium, choline (betaines A61K31/205)
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61Q 17/04: Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The present invention relates to compositions comprising a methyl group donor compound and an acetyl-CoA donor compound for use in therapy and prevention of diseases associated with dysfunction of mitochondriae, wherein the diseases associated with dysfunction of mitochondriae are nucleotide excision repair deficiency syndromes, especially Xeroderma pigmentosum A, or DNA repair deficiency syndrome ataxia telangiectasia associated with mitochondrial dysfunction. Particularly, the composition is used for therapy of nucleotide excision repair deficiency syndromes, such as Xeroderma pigmentosum A, B, C, D, E, F, G, V, the different forms of Cockayne syndrome (CS), such as Cockayne syndrome type B (CSB) and Cockayne syndrome type A (CSA), and trichothiodystrophy (TTD), or DNA repair deficiency syndrome ataxia telangiectasia associated with mitochondrial dysfunction.

## Claims

### Claim 1

A method for the treatment of a disease associated with dysfunction of mitochondriae, comprising administering i) a first compound A, which is a methyl group donor, and
ii) a second compound B, which is an acetyl-CoA donor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first compound A is selected from the group consisting of a trimethylamine, sarcosine, a trimethylamine-N-oxide, serine, and mixtures of two or more of them.

### Claim 3 (depends on 1)

The method of claim 1, wherein the second compound B is selected from fatty acids, fatty acid derivatives, salts of fatty acids, salts of fatty acid derivatives, triglycerides, triglyceride derivatives, and dicarboxylic acid derivatives.

### Claim 4 (depends on 1)

The method of claim 1, wherein the molar ratio of compound A to compound B is from 10:1 to 1:10.

### Claim 5 (depends on 1)

The method of claim 1, wherein the administration is orally, intravenously, or topically.

### Claim 6 (depends on 1)

The method of claim 1, wherein the concentration of compound A is in the range of from 5 to 250 mM and the concentration of compound B is in the range of from 1 to 100 mM.

### Claim 7 (depends on 1)

The method of claim 1, wherein the disease associated with dysfunction of mitochondriae is selected from one or more of:
i) nucleotide excision repair deficiency syndromes, and
ii) DNA repair deficiency syndrome ataxia telangiectasia.

### Claim 8 (depends on 7)

The method of claim 7, wherein the nucleotide excision repair deficiency syndrome is:
i) Xeroderma pigmentosum A,
ii) Xeroderma pigmentosum B,
iii) Xeroderma pigmentosum C,
iv) Xeroderma pigmentosum D,
v) Xeroderma pigmentosum E,
vi) Xeroderma pigmentosum F,
vii) Xeroderma pigmentosum G,
viii) Xeroderma pigmentosum V,
ix) Cockayne syndrome type A,
x) Cockayne syndrome type B, or
xi) trichothiodystrophy (TTD).

### Claim 9 (depends on 2)

The method of claim 2, wherein compound A is a trimethyl ammonium compounds or a mixture of two or more trimethyl ammonium compounds.

### Claim 10 (depends on 2)

The method of claim 2, wherein compound A is one or more of choline and betaine.

### Claim 11 (depends on 3)

The method of claim 3, wherein compound B is selected from the group consisting of acetate, butyrate, triheptanoin, dimethyl-α-ketoglutarate, and pyruvate dehydrogenase kinase inhibitors.

### Claim 12 (depends on 4)

The method of claim 4, wherein the ratio is selected from:
i) 8:1 to 1:8,
ii) 5:1 to 1:5,
iii) 2:1 to 1:2, or
iv) 1:1.

### Claim 13 (depends on 5)

The method of claim 5, wherein the administration is topical.

### Claim 14 (depends on 13)

The method of claim 13, wherein the administration further comprises administering a sunscreen product.

### Claim 15

A pharmaceutical composition comprising:
a first compound A, which is a methyl group donor, and
a second compound B, which is an acetyl-CoA donor.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15, wherein compound A is selected from the group consisting of one or more of a trimethylamine, sarcosine, trimethylamine-N-oxide, serine, and mixtures thereof.

### Claim 17 (depends on 15)

The pharmaceutical composition of claim 15, wherein compound B is selected from the group consisting of fatty acids, fatty acid derivatives, salts of fatty acids, salts of fatty acid derivatives, triglycerides, triglyceride derivatives, dicarboxylic acid derivatives, and mixtures thereof.

### Claim 18 (depends on 15)

The pharmaceutical composition of claim 15, wherein the molar ratio of compound A to compound B is from:
i) 10:1 to 1:10,
ii) 8:1 to 1:8,
iii) 5:1 to 1:5,
iv) 2:1 to 1:2, or
v) 1:1.

### Claim 19 (depends on 15)

The pharmaceutical composition of claim 15, wherein the composition is formulated for oral, intravenous, or topical administration.

### Claim 20 (depends on 15)

The pharmaceutical composition of claim 15, wherein the concentration of compound A is in the range of from 5 to 250 mM and the concentration of compound B is in the range of from 1 to 100 mM.
